Leonardo Pantoni
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
INTRODUCTION Vascular cognitive impairment (VCI) is a common, heterogeneous condition, currently lacking approved treatments. METHODS We reviewed therapeutic strategies tested in VCI and meta‐analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration. RESULTS One‐hundred seventy‐three trials were extracted (22,347 participants, four VCI categories, 91 interventions, 145 outcomes). Ginkgo biloba extracts showed large to moderate improvements in cognition (Cohen's d : 0.83, 95% CI: 0.00 to 1.67) and small to moderate improvements in functional outcomes (Cohen's d : 0.50, 95% CI: 0.25 to 0.75). Small to moderate improvements in cognition were shown for acetylcholinesterase inhibitors, memantine, cerebrolysin, propentofylline, physical exercise, and cognitive rehabilitation. DISCUSSION VCI clinical trials exhibited substantial heterogeneity. Few interventions were reproducibly tested in adequately sized and designed studies. Nonetheless, some interventions showed modest effects on global cognition and functional outcomes. To enhance the likelihood of success, future studies should focus on promising interventions with a solid rationale, target specific VCI subtypes, improve statistical power, and reduce heterogeneity. Highlights Considerable methodological heterogeneity across VCI trials undermined the strength of evidence for both positive and negative findings, ultimately decreasing confidence in the possibility of treating VCI. Ginkgo biloba extracts have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low. Future trials should focus on a single VCI subtype, prioritize interventions with a strong mechanistic rationale, standardize diagnostic criteria, ensure adequate power for chosen outcomes, test against placebo, and implement FAIR data sharing to accelerate therapeutic discovery.
Year:
2025
Background Long‐term continuous monitoring with insertable cardiac monitor (ICM) is recommended after cryptogenic stroke (CS) by current guidelines to detect subclinical atrial fibrillation (SCAF). However, long‐term real‐world data on ICM‐SCAF detection and ensuing therapy are limited. The aim of this study was to assess long‐term SCAF detection rate in a large cohort of CS patients with ICM. Methods Data of consecutive CS patients receiving ICM from September 2016 to February 2024 in 20 Italian centers were collected. Patients were followed with remote and outpatient follow‐up according to clinical practice. SCAF was diagnosed if a device‐detected SCAF daily burden ≥ 5 min was confirmed by a cardiologist. Results Seven hundred and eighty‐nine CS patients with ICM (mean age 69.3 ± 11.7 years, 40.3% females, 79.0% CHA 2 DS 2 ‐VASc score ≥ 4) were monitored for a mean of 27.3 (IQR:14.2–42.5) months after index stroke. SCAF was diagnosed in 229 (29.0%) patients, with a cumulative detection rate of 37.0% (IQR: 32.9%–41.5%) 48 months after the stroke, and was asymptomatic in 198 (86.5%). Sixty‐eight (29.7%) patients had one or more days with a 24‐h SCAF burden. Median time from index stroke to SCAF diagnosis was 6.9 (IQR: 2.1–17.0) months. After SCAF diagnosis, anticoagulants were prescribed to 210 (95.9%) patients out of 219 not already assuming them at baseline. CHA 2 DS 2 ‐VASc ≥ 5, anterior circulation stroke, and cortical lesions were independent predictors of SCAF diagnosis. Conclusions This multicenter real‐world project confirmed that ICM allows the detection of SCAF in one third of CS patients 48 months after the stroke, leading to anticoagulation in most of them.
Year:
2025
Background: In patients with cryptogenic stroke (CS) or transient ischemic attack (TIA), prolonged cardiac monitoring is recommended to improve detection of atrial fibrillation (AF). Prediction scores have been proposed to identify patients with a high likelihood of post-stroke AF detection and some of them have been used to guide the selection of patients for implantable loop recorders (ILR), but few studies have externally assessed their performances. Aims: Aim of this prospective cohort study was to assess the performance of nine AF prediction scores in a cohort of CS and TIA monitored with ILR. Methods: Patients were included after a diagnosis of CS or TIA and ILR implantation between July 2018 and December 2023. Nine AF prediction scores were evaluated: STAF, LADS, HAVOC, Brown-ESUS AF, AS5 F, C 2 HEST, CHASE-LESS, AF-ESUS, and Empoli ESUS-AF. For each score we calculated sensitivity, specificity, negative (NPV) and positive predictive value (PPV), overall accuracy, and area under the receiver operating characteristic curve (AUROC). AUROCs were compared with DeLong’s test. Results: Of 1032 admitted patients, 270 (26.2%) were defined cryptogenic, 194 of whom (71.9%) received an ILR (43.3% women; median age 74.0 years [IQR 65.8-82.0]; median NIHSS score on admission 3.0 [1.0-6.0]; 182 (93.8%) ischemic stroke and 12 (6.2%) TIA). Median time from index event to ILR implant was 10 days (7-37). During long-term monitoring (median follow-up 23.0 months [12.0-37.3]), AF was detected in 62 patients (32%), with a median time from index stroke to AF diagnosis of 4.0 months (1.0-11.3). Sensitivity of the scores ranged between 12.9% and 95.2%, specificity 12.9-67.7%, PPV 37.3-48.1%, NPV 68.6-90.6%, and overall accuracy 45.4-66.3%. The Brown ESUS-AF score reached the highest AUROC (0.697 in the whole cohort, 0.707 in the ischemic stroke subgroup). In patients with ischemic stroke, AUROC was higher for Brown ESUS-AF compared to HAVOC (p = 0.014), CH 2 EST (p = 0.002), and Empoli ESUS-AF (p = 0.015) and for LADS (AUROC = 0.690) compared to CH 2 EST (p = 0.039) and Empoli ESUS-AF (p = 0.015). Conclusions: AF prediction scores based on clinical and cardiovascular imaging parameters do not predict AF detection with adequate accuracy in patients with CS or TIA and ILR. Brown ESUS-AF and LADS scores demonstrated a better performance compared to other prediction scores.
Year:
2025
Objective Cognitive and psychiatric symptoms have been increasingly reported after severe acute respiratory syndrome coronavirus 2 infection, developing soon after infection and possibly persisting for several months. We aimed to study this syndrome and start implementing strategies for its assessment. Methods Consecutive patients, referred by the infectious disease specialist because of cognitive complaints after COVID-19, were neurologically evaluated. Neurological evaluation included a cognitive screening test (Montreal Cognitive Assessment, MoCA). Moreover, patients were invited to fill out a general symptom questionnaire and a self-administered multidimensional assessment of psychiatric symptoms, followed by a full psychiatric assessment if scores were above validated cutoffs. Results Of 144 referred patients, 101 (mean age 55.2±13.1, 63.4% females) completed the cognitive screening and the self-administered psychiatric questionnaire. Acute infection severity was low for most patients and the most common persisting symptoms were fatigue (92%), sleep problems (69.5%), and headache (52.4%). MoCA outlined cognitive deficits in ≥1 cognitive domain in 34% of patients, mainly in memory and attention. About 60% of patients presented depressive, anxiety, or stress-related symptoms. Psychiatric scale scores significantly correlated with overall symptom burden and MoCA score. No significant correlation was found between MoCA scores and overall symptom burden. Conclusion We hypothesize that persistent cognitive complaints after COVID-19 might reflect a concomitant or reactive psychopathological condition, possibly coupled with an infection-related impact on cognitive functions. The application of a combined neurological and psychiatric assessment seems crucial to appraise the nature of post-COVID-19 condition.
Year:
2024
Objective Cognitive and psychiatric symptoms are frequently reported after SARS-CoV-2 infection, but their interplay has been only partially explored. We investigated frequency and severity of psychiatric symptoms in patients with persistent cognitive complaints after COVID-19. Methods We conducted a cross-sectional study. Neurologists assessed 101 patients reporting cognitive symptoms after COVID-19. Patients were invited to fill a screening battery with self-reported psychometric scales (Depression Anxiety Stress Scales-21, Impact of Event Scale-Revised, Insomnia Severity Index). Patients scoring above validated cut-offs in ≥1 scale were referred to psychiatrists who administered the Mini-International Neuropsychiatric Interview (M.I.N.I.), Hamilton Anxiety (HAM-A), and Hamilton Depression (HAM-D) rating scales and asked to complete the Personality Inventory for DSM-5-Brief Form (PID-5-BF). Results Out of the 57 referred patients, 38 (64.4%) accepted to undergo the psychiatric examination. Among these, 18 (47.4%) were diagnosed with adjustment disorder (23.7%), anxiety disorder (10.5%), major depressive disorder (7.9%), and post-traumatic stress disorder (2.6%). Pharmacologic treatment before post-COVID condition (present in 12 patients, 31.6%) was associated with a score above cut-off on the HAM-A and HAM-D scales. A longer duration of untreated psychiatric illness after COVID-19 was associated with worse scores on the same scales. Patients with a higher PID-5-BF total score had a higher probability of receiving a psychiatric diagnosis. Conclusion Almost half of patients with post-COVID-19 conditions reporting cognitive symptoms were found to suffer from a psychiatric condition after psychiatric evaluation. The application of a psychiatric screening in a population suffering from long-term effects of COVID-19 can lead to early diagnosis and timely treatment.
Year:
2024
Background The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF. Methods We combined patient data from the RAF and RAF-NOAC studies, prospective observational studies conducted across Stroke Units in Europe, the United States, and Asia from January 2012 to June 2016. We included consecutive patients with AF who suffered an acute ischemic stroke with a follow-up of 90 days. Our outcomes were the combined endpoint, including stroke, transient ischemic attack, systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial bleeding. Furthermore, both ischemic and hemorrhagic outcomes were evaluated separately. Results A total of 1.742 patients were included (46% male), and 898 (52%) received statins after the index event. At multivariable analysis, statin use was statistically associated with age (OR 0.92, 95% CI 0.97 - 0.99, p = 0.001), male sex (OR 1.35, 95% CI 1.07 - 1.70, p = 0.013), anticoagulation (OR 2.53, 95% CI 1.90 - 3.36, p <0.0001), hyperlipidemia (OR 5.52, 95% CI 4.28 - 7.12, p <0.0001), paroxysmal AF (OR 1.40, 95% CI 1.12 - 1.75, p = 0.003), leukoaraiosis (OR 1.39, 95% CI 1.11 - 1.75, p = 0.004) and heart failure (OR 0.72, 95% CI 0.53 - 0.98, p = 0.034). Statin use was not associated with the combined outcome event (OR 0,81, 95% CI 0,56 – 1,19, p = 0.286) and ischemic outcome event (OR 1,13, 95% CI 0,71 – 1,82, p = 0.604) while was associated with a lower risk of hemorrhagic outcome event (OR 0,49, 95% CI 0,27 – 0,88, p = 0.016). Conclusions Our data show that statins seem to protect against global bleeding events in cardioembolic stroke patients; this may be due to the pleiotropic effect of statins. More data are warranted to confirm these findings.
Year:
2024
Introduction Vascular cognitive impairment (VCI) is a common and heterogeneous condition, clinically and pathophysiologically, that still lacks approved treatment. Methods We reviewed evidence from randomized and non‐randomized clinical trials in VCI to explore whether any therapeutic option warrants further investigation and to assess possible flaws in previous studies. Results We identified 118 studies after searching PubMed and Embase, including 19,223 participants and 5 different VCI subtypes. We found 63 different types of intervention (51 pharmacologic, 5 employing physical agent application, 7 rehabilitation approaches) compared with either placebo, best medical treatment, or other interventions. Treatment efficacy was assessed through 125 outcome measures (with a clearly pre‐specified primary outcome in 50.8% of studies). Discussion Therapeutic trials in VCI have been heterogeneous in terms of populations, types of interventions, and outcomes. Overall, a lack of clear pathophysiological rationale for tested interventions seems to emerge, together with the need to homogenize trial study design
Year:
2023
Collaborators (37)
Simona Sacco
Full Professor of Neurology - Head of the Clinical Neurology Unit
University of L'Aquila
Danilo Toni
Full Professor of Neurology
Sapienza University
Alessandro Pezzini
Associate Professor of Neurology
University of Parma
Walter Ageno
Associate Professor
University of Insubria
Davide Strambo
-
George Ntaios
Professor of Internal Medicine
University of Thessaly
Sung Il Sohn
Professor
Keimyung University Dongsan Medical Center
Theodoros Karapanayiotides
Associate Professor
Aristotle University of Thessaloniki
Georgios Tsivgoulis
-
Piergiorgio Lochner
Head of Neurointensive Care Unit Unit and Neurosonology Lab
Saarland University
Patrik Michel
Associate Professor
Lausanne University Hospital
Eugenia Rota
Chief
-
Jukka Putaala
-
Maria Kosmidou
Ass Professor
Aristotle University of Thessaloniki
Brian Mac Grory
Assistant Professor
Duke University School of Medicine
Azmil H Abdul-Rahim
University of Glasgow
Gian Marco De Marchis
Head of Personal Board
University Hospital Basel
MARINA DIOMEDI
Associate Professor, Tor Vergata University
University of Rome Tor Vergata
Laetitia Yperzeele
Antwerp University Hospital
Stefan Engelter
Chair Department Rehabilitation & Neurology and Head of Stroke Treatment Pathyway
-
Sotirios Giannopoulos
Professor fo Neurology
National and Kapodistrian University of Athens
Lina Palaiodimou
National and Kapodistrian University of Athens
Jesse Dawson
Professor of Stroke Medicine
University of Glasgow
Yuriy Flomin
Professor
ukraine; shupyk national healthcare university of ukraine
Turgut Tatlisumak
Professor
Göteborgs Universitet
Isabella Canavero
Fondazione IRCCS Istituto Neurologico Carlo Besta
Daniel Strbian
-
PANAGIOTIS HALVATSIOTIS
Associate Professor
National and Kapodistrian University of Athens - Faculty of Medicine
Maurizio Paciaroni
Docenti di ruolo di IIa fascia
University of Ferrara
Konstantinos Vadikolias
Professor
Democritus University of Thrace
Maurizio Acampa
University of Siena
PIERLUIGI BERTORA
Assistant professor
Università degli Studi di Torino
David Seiffge
-
Andrea Morotti
-
Bernardo Dell’Osso
Associate Professor of Psychiatry
University of Milan
Alexandros Polymeris
Attending Neurologist
University Hospital Basel
Manuel Cappellari
-
Make your next move.
Prepare your application
Review drafts before you send them.